Industry reports
Editor highlights

Search inside this page

Publishers

All regions

Free Market Research Guides to Download

Pathology Analysis & Statistics, March 2014 (p2)

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

31-80 of about 5 600 reports
NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool

  • $ 3 500
  • Industry report
  • March 2014
  • by GBI Research

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool Summary GBI Research, the leading business intelligence ...

  • Industries : Pathology
  • Countries : World
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth

  • $ 3 500
  • Industry report
  • February 2014
  • by GBI Research

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth Summary GBI Research, a leading business intelligence provider, ...

  • Industries : Pathology
  • Countries : World
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • $ 3 500
  • Industry report
  • January 2014
  • by GBI Research

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Summary GBI Research, has released the ...

  • Industries : Pathology
  • Countries : World
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States, United Kingdom
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Japan, World, United States
Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, United States, India, China
Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, India, China, Europe
Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : China, World, Spain, Italy, France, Germany, United States, Canada, India, Europe
Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, United States, United Kingdom, India, China, Europe
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech

  • $ 3 295
  • Industry report
  • February 2014
  • by Currentpartnering

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: Migraine - Current and Future Players

PharmaPoint: Migraine - Current and Future Players

  • $ 2 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Migraine - Current and Future Players”. The report is a vital source of up-to-date ...

  • Industries : Pathology
  • Countries : World
Cardiovascular Partnering Terms and Agreements

Cardiovascular Partnering Terms and Agreements

  • $ 2 995
  • Industry report
  • March 2014
  • by Currentpartnering

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Cardiovascula ...

  • Industries : Pathology

» View Public Reports

About 12 000 reports

U.S. Pharmaceutical Industry Analysis

  • Industry report
  • April 2014
  • 129 pages

... Of work are implicated as important causes of hypertension, as well as cvd., E.G. Job strain 96 schnall pl et al. Why the workplace and cardiovascular disease. In: schnall pl, belkic kl, landsbergis pa ...


» Read our Company Profiles

About 200 Companies

GlaxoSmithKline P.L.C.

United States

Novartis Inc.

Switzerland

GlaxoSmithKline PLC

United Kingdom

Pfizer Inc.

United States

Johnson and Johnson

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.